Partnership and collaboration are integral to the success of our mission.
Led by Professor Susan Rosser, our hub unites academic excellence across renowned institutions, each bringing unique expertise and strengths.
To ensure our research is not only theoretically ground-breaking but also practically impactful we have and are developed partnerships with industry leaders and non-profit organisations.
We also work on joint initiatives with other UKRI-Funded “Mission” Engineering Biology Hubs.
Oxford focuses on improved delivery mechanisms for gene therapies, including viral vectors. They have a strong track-record translating research into clinical applications, including for rare lung diseases and liver diseases.
Imperial College London focuses on novel engineered delivery mechanisms for gene therapy and the use of a patented gene regulation technology for oncology applications.
CRUK Scotland Institute provides strong translational, subject matter expertise in oncology as well as accesses to state of the art cancer research tools and models.
The University of Edinburgh is a UK and global leader in engineering biology, hosting the largest and most comprehensive group of researchers in the country.
We benefit from our close interaction and integration with the University of Edinburgh's Centre for Engineering Biology. This community of over 50 research groups and 200 researchers take engineering biology concepts and translate them into real world solutions. Several of our Hub scientists are affiliated with the centre.
Our research is underpinned by our ability to access to Edinburgh Genome Foundry, a unique, fully automated robotic platform for DNA assembly, cell engineering and phenotyping.
Our Foundry has developed a world-renowned suite of software for the design and automation of genetic constructs.
To disseminate and make our research accessible to the public, patients, and researchers, we are working with EURO GCT, an Edinburgh-based non-profit organisation that provides reliable and accessible information about the use of cells and genetic material to treat disease.
Social scientists are uniquely integrated into our hub and explore the social, political, and ethical dimensions of our research. They bring valued social science research expertise applied to engineering biology and play a crucial role in developing our capacity for responsible research and innovation.
Beyond our key partners, our research is underpinned by our collaborations with experts in the field, enabling networks (e.g EURO GC and MRC REACT) and access to state-of-the-art facilities.
To translate our research into clinical applications, we are also working closely with the MRC/BHF Centre of Research Excellence in Advanced Cardiac Therapies (REACT). The £50M centre is set to develop the first therapies to stimulate heart repair and regeneration in patients with heart disease and accelerate delivery of gene therapies for heart disease.
The University of Oxford’s Clinical Biomanufacturing Facility, is a GMP facility that holds all required authorisations and licenses to manufacture a variety of novel biotech products. This includes viral vectors and recombinant protein vaccines and advanced therapy medicinal products (ATMPs) such as cell and gene therapy products for use in phase I/II clinical trials.
We want to work with clinicians, industry and relevant stakeholders who can help our tools to reach the clinic.
This article was published on
